** Shares of Eris Lifesciences ERIS.NS fall 4.5% to 1,368.10 rupees
** Company said Croatia's medicines regulator flagged non-compliance observations at its subsidiary Swiss Parenterals' Unit-1 and Unit-2 injectables facilities in Ahmedabad, Gujarat
** Says observations are procedural, remediation underway
** May delay commercialisation of EU-CDMO product pipeline, co says; adds, minimal impact expected on existing business
** ERIS rated "buy" on average by 10 analysts, median PT 1,773 rupees - data compiled by LSEG
** YTD, stock down about 5%
(Reporting by Surbhi Misra in Bengaluru)
((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))